ClinicalTrials.Veeva

Menu
R

Red Oak Psychiatry Associates | Houston, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cariprazine
PRC-063
SPD489
SHP465
Fluoxetine
Aticaprant
BMS-820836
L1-79
Levomilnacipran
Seltorexant

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 19 total trials

A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

This study will investigate the efficacy, safety and tolerability of L1-79 in participants aged 12-21 years who have been diagnosed with ASD with a s...

Active, not recruiting
Autism Spectrum Disorder
Autism
Drug: L1-79
New

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Enrolling
Anhedonia
Depressive Disorder, Major
Drug: Aticaprant
Other: Placebo

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizop...

Enrolling
Bipolar I Disorder
Schizophrenia
Drug: Cariprazine Flexible Dose
Locations recently updated

Autism spectrum disorder (ASD) consists of deficits in social, communication, and cognitive development, repetitive and stereotypic behaviors. Many A...

Enrolling
Autism Spectrum Disorder
Drug: Placebo
Drug: Cariprazine

Trial sponsors

AbbVie logo
R
Shire logo
Janssen (J&J Innovative Medicine) logo
Bristol-Myers Squibb (BMS) logo
Forest Laboratories logo
N
N
S
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems